Purging of human breast cancer cells from stem cell products with an adenovirus containing p53

被引:0
作者
Manabu Hirai
Linda S Kelsey
Mei Vaillancourt
Daniel C Maneval
Tsutomu Watanabe
James E Talmadge
机构
[1] University of Nebraska Medical Center,Department of Pathology and Microbiology
[2] Canji Inc.,Department of Pediatrics
[3] Tokushima University Hospital,undefined
来源
Cancer Gene Therapy | 2000年 / 7卷
关键词
Adenovirus; breast cancer; clonogenic growth; p53; purging.;
D O I
暂无
中图分类号
学科分类号
摘要
Tumor cell contamination of stem cell products can contribute to tumor relapse following high-dose chemotherapy and stem cell rescue. Numerous techniques have been used to remove the tumor cells from stem cell products with the objective of prolonging relapse-free survival. However, to date these techniques have been relatively ineffectual and/or toxic to hematopoietic stem and progenitor cells. The differential infectivity of adenovirus (Adv) vectors for breast cancer cells, compared with hematopoietic cells, has suggested that Adv-p53 might provide an effective purging strategy. To facilitate the use of Adv-p53 as a clinical strategy, we undertook studies to determine the parameters necessary for optimal stem cell product purging. The parameters studied were the particle number to nucleated cell ratio, the duration of coincubation, the incubation volume, and the presence or absence of hematopoietic progenitor cells. We have found that these parameters are interdependent and conclude that a 4-hour coincubation with an Adv-p53 particle to nucleated cell ratio of 2000:1 with 2 × 108 nucleated cells/mL is optimal for tumor cell purging. Furthermore, this appeared to be a safe procedure, with total loss of clonogenic growth of breast cancer cells as well as no significant effect on progenitor cell function as determined by granulocyte-macrophage colony-forming unit assays.
引用
收藏
页码:197 / 206
页数:9
相关论文
empty
未找到相关数据